

A cohort study of forced vital capacity, airway obstruction, and survival in the multinational Burden of Obstructive Lung Disease study

Peter G.J. Burney^{1,*}, Emmanouil Bagkeris^{1, }, James Potts¹, Rune Nielsen^{2,3}, Graham Devereux⁴, Karima El Rhazi⁵, Althea Aquart-Stewart⁶, Asaad A. Nafees^{7, }, Parvaiz Koul⁸, Padukudru Anand Mahesh⁹, Dhiraj Agarwal¹⁰, Sanjay Juvekar^{10,11}, Thorarinn Gislason^{12,13}, Meriam Denguezli¹⁴, Imed Harrabi¹⁵, Stefanni Nonna M. Paraguas^{16,17}, Rain Jogi¹⁸, Gregory Erhabor¹⁹, A. Sonia Buist²⁰, Christer Janson²¹, Andre F.S. Amaral^{1,22, }, on behalf of the BOLD Collaborative Research Group[†]

¹National Heart and Lung Institute, Imperial College London, London, United Kingdom

²Department of Clinical Science, University of Bergen, Bergen, Norway

³Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway

⁴Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

⁵Department of Epidemiology and Public Health, Faculty of Medicine, Dentistry and Pharmacy, Sidi Mohamed Ben Abdillah University, Hassan II University Hospital Center of Fez, Fez, Morocco

⁶Department of Medicine, University of the West Indies, Mona Campus, Kingston, Jamaica

⁷Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan

⁸Department of Pulmonary Medicine, Sheri Kashmir Institute of Medical Sciences, Srinagar, India

⁹Department of Respiratory Medicine, JSS Medical College, Mysuru, Karnataka, India

¹⁰Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India

¹¹Dr D.Y. Patil Medical College, Hospital and Research Centre, Dr D.Y. Patil Vidyapeeth, Pimpri, Pune, India

¹²Faculty of Medicine, University of Iceland, Reykjavik, Iceland

¹³Department of Sleep, Landspítali University Hospital, Reykjavik, Iceland

¹⁴Faculté de Médecine Dentaire de Monastir, Université de Monastir, Monastir, Tunisia

¹⁵Ibn El Jazzar Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia

¹⁶Philippine College of Chest Physicians, Quezon City, Philippines

¹⁷Philippine Heart Centre, Quezon City, Philippines

¹⁸Lung Clinic, Tartu University Hospital, Tartu, Estonia

¹⁹Department of Medicine, Obafemi Awolowo University/Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Osun State, Nigeria

²⁰School of Medicine, Oregon Health and Science University, Portland, OR, United States

²¹Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden

²²NIHR Imperial Biomedical Research Centre, London, United Kingdom

*National Heart and Lung Institute, Imperial College London, Hammersmith Campus, 422, Dr Victor Phillip Dahdaleh Building, London W12 0NN, United Kingdom. E-mail: p.burney@imperial.ac.uk

[†]Members listed in the [Supplementary Material](#).

Abstract

Background: In the USA, higher forced vital capacity (FVC) is linked with longer survival, and FVC is associated with survival independently of ethnicity. The implications for the low FVC values in parts of Asia and Africa are unknown.

Methods: We used data from 16 sites of the multinational Burden of Obstructive Lung Disease (BOLD) study that completed follow-up of participants between 2019 and 2021 and reported at least five deaths between baseline and follow-up. We assessed the association of mortality with FVC and Forced Expiratory Volume in 1 second (FEV₁)/FVC ratio within each site using Cox proportional hazards models. These models were adjusted for age, smoking, height, and weight. Effect estimates from all sites were combined using meta-analysis. Systematic regional differences were investigated.

Results: Of 9927 study participants with follow-up data, 1120 (11.3%) had died [mean follow-up = 8.7 years, standard deviation (SD) = 3.3 years]. Baseline post-bronchodilator FVC and FEV₁/FVC were inversely associated with mortality. When both FVC and FEV₁/FVC were mutually adjusted for each other, the decreased mortality rates were more pronounced for

each SD higher FVC at baseline [44% (95% confidence interval (CI): 25%, 58%) for men and 28% (95% CI: 11%, 41%) for women] than for FEV₁/FVC at baseline [14% (95% CI: 8%, 20%) for men and 7% (95% CI: -10%, 21%) for women]. The probability of true regional differences was low.

Conclusions: People with a higher FVC adjusted for age, sex, and height have a longer survival. Regional adjustments to lung function standards are inappropriate when assessing prognosis.

Keywords survival analysis, vital capacity, airflow obstruction, multinational, lung function

Key messages

- This research aimed to identify which spirometric measure [forced vital capacity (FVC) or forced expiratory volume in 1 second to FVC ratio (FEV₁/FVC)] better predicts longevity and to test whether this is consistent across populations.
- We found that low FVC has a clearer association with mortality, with comparable results across populations.
- Our findings suggest that much of the mortality ascribed to chronic obstructive pulmonary disease in Asia and Africa is likely not due to airflow obstruction but rather due to low FVC.

Introduction

Forced vital capacity (FVC) is a widely available spirometric measurement that is an approximation of the size of the lung (total lung capacity), and, in the USA, this is more closely related to survival than is the Forced Expiratory Volume in 1 second (FEV₁) or FEV₁ to FVC ratio (FEV₁/FVC) [1–3]. The FVC is used clinically to identify restrictive lung disease but can also be used to assess the ‘severity’ of disease. The GOLD guidelines suggest the FEV₁% predicted rather than the FEV₁/FVC ratio to assess the severity of obstruction (<https://GOLD COPD.org>), and we would argue that FEV₁ is in effect acting as a surrogate for FVC or TLC, with which it is strongly correlated.

In the USA, it has been shown that although there are marked differences in ‘normal values’ between ‘White’ (European-American) and African-American populations, the prognostic significance of a given FVC is the same for a European-American and African-American individual of the same height, age, and sex [4–6]. There is, however, little information outside the USA on which to judge whether this equality of risk between populations is more generally the case.

Based on data from the Burden of Obstructive Lung Disease (BOLD) baseline survey, we have shown that ‘normal values’ of lung function can be divided into four relatively homogeneous world regions: ‘Europe’ (and high-income countries with predominant migration from Europe), ‘Near East’ (including Western and Central Asia and North Africa), ‘Sub-Saharan Africa’ (including the Caribbean), and ‘Far East’ (including South, South-East, and East Asia) [7]. Although the relation of FVC to age and height is different in each of these regions, it is not known whether this affects the relation of the FVC to survival.

Now, we have used data from the baseline and the follow-up of the BOLD cohort to test which baseline spirometric measurement, FVC or FEV₁/FVC ratio, has the strongest association with longevity, and to test whether, after stratifying for sex and adjusting for age, smoking status, height, and weight, these show similar effects in different populations. The answers to these questions will determine whether universal standards are possible for spirometry and which those standards should be.

Methods

Study population

The data presented here are from the 2019–21 follow-up of individuals initially studied in selected sites from the BOLD study (2003–16) [8]. Full details are provided elsewhere [9]. The initial selection of sites for BOLD was based on the ability to undertake the study and was intended to cover all major world regions. In each site, a representative sample was selected of all those who were aged 40 years and over and were not institutionalized. Sites were selected for follow-up if they were in low- or middle-income countries [Benin, India (three sites), Jamaica, Kyrgyzstan (2 sites), Malawi, Morocco, Nigeria, Pakistan, the Philippines, Sudan, and Tunisia] or in the Nordic region (Iceland, Norway, Sweden, and Estonia). Those with complete spirometry data at the BOLD baseline visit were invited for follow-up. There was a single follow-up in each site.

Mortality data

The endpoint was death from any cause other than accidents or violence. Mortality was based on questions asked to the household members and neighbours, including cause of death and time of death. Among the Nordic sites, the date of death was provided by the country’s death registry. If the date of death was not recorded, the date of death was estimated as halfway between the BOLD baseline visit and the follow-up when the death was reported.

Lung function data

Lung function (FEV₁ and FVC, and FEV₁/FVC) was measured using an EasyOne spirometer (ndd Medizintechnik AG, Zurich, Switzerland), pre and postadministration of 200 mcg salbutamol through an inhalation chamber. All curves were centrally reviewed and scored based on ATS/ERS acceptability and repeatability criteria current at the time. As chronic obstructive pulmonary disease has generally been identified with obstruction that is not reversed by bronchodilators, we used postbronchodilator values in the analysis.

Statistical analysis

Data were expressed as means and standard deviation (SD). Sex-specific univariable and multivariable Cox proportional hazard models were used to assess the association of FVC and FEV₁/FVC ratio with mortality. The multivariable models were adjusted for age, smoking status, height, and weight. Inverse probability weighting was used to take account of variable follow-up of the sample [10, 11]. The results across all sites were summarized using random effects meta-analysis, and we used forest plots to explore the between-site variation in the association of FVC and FEV₁/FVC with mortality.

To estimate absolute mortality rates at baseline (rather than just Hazard Ratios), we used a fully parametric Gompertz regression model. Mortality rates were adjusted for age and height. For illustration, we plotted mortality at age 55 years and at a typical height (170 cm for men and 160 cm for women). To illustrate the association, we drew graphs of mortality against FVC expressed as centiles for men and women separately. FVC centiles were estimated from z-scores in an earlier BOLD analysis of baseline lung function in relation to sex, age, and height-squared [7].

The statistical analysis was performed using Stata, version 17.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Of 12 502 eligible individuals, 2540 (20.3%) were lost to follow-up, and 35 (0.3%) died as a result of accidents or violence (Fig. 1). These were excluded from all further analysis (Supplementary Table 1, in the supplementary material). Those lost to follow-up were slightly older and substantially more likely to be never smokers, but were otherwise similar at baseline to those who were followed up. Of the remaining 9927, 1120 (11.3%) had died from other causes (Table 1). Participants who were either unwilling to participate in the follow-up study or were known to be living away from their original address were included in the survival analysis if their vital status was known.

Table 2 gives the baseline information on the 4572 men and 5355 women included in the survival analysis. The mean ages of




Figure 1 Flow diagram showing inclusion and exclusion from study.

Table 1 Follow-up time and crude mortality for participants stratified by sex and Burden of Obstructive Lung Disease study site.

A. Men					
Site	Total included, <i>n</i> (%)	Survived, <i>n</i> (% of included)	Died, <i>n</i> (% of included) ^a	Follow-up time, years, mean (SD)	Crude mortality rate per 100 000 individuals per year
Benin (Sèmè-Kpodji)	279 (91)	270 (97)	9 (3)	6.37 (0.58)	506
Estonia (Tartu)	313 (100)	199 (64)	114 (36)	9.21 (2.72)	3955
Iceland (Reykjavik)	364 (90)	265 (72)	99 (27)	12.93 (3.55)	2103
India (Kashmir)	76 (18)	66 (87)	10 (13)	9.48 (1.58)	1388
India (Mysore)	257 (99)	242 (94)	15 (6)	7.47 (2.94)	780
India (Pune)	496 (98)	425 (86)	71 (14)	10.37 (1.99)	1380
Jamaica	143 (57)	138 (96)	5 (3)	5.67 (0.73)	617
Kyrgyzstan (Chui)	257 (91)	241 (94)	16 (6)	6.21 (0.85)	1003
Kyrgyzstan (Naryn)	318 (96)	293 (92)	25 (8)	6.04 (0.86)	1302
Malawi (Chikwawa)	206 (90)	187 (91)	19 (9)	4.58 (0.89)	2014
Morocco (Fes)	112 (32)	112 (100)	0 (0)	10.70 (0.97)	n/a
Nigeria (Ife)	334 (97)	307 (92)	27 (8)	8.10 (1.17)	998
Norway (Bergen)	308 (94)	235 (76)	73 (23)	13.07 (3.90)	1,813
Pakistan (Karachi)	221 (81)	196 (88)	25 (11)	4.20 (0.81)	2,693
Philippines (Nampicuan-Talugtug)	354 (98)	290 (82)	64 (18)	9.84 (2.13)	1,837
Sudan (Khartoum)	42 (14)	40 (95)	2 (5)	7.72 (0.57)	617
Sweden (Uppsala)	263 (92)	237 (90)	26 (10)	12.33 (2.32)	802
Tunisia (Sousse)	229 (74)	202 (88)	27 (12)	10.14 (1.44)	1,163
Total	4572 (78)	3945 (86)	627 (14)	8.89 (3.46)	1543
Total^b	4418 (85)	3793 (86)	625 (14)	8.86 (3.50)	1597
B. Women					
Site	Total included, <i>n</i> (%)	Survived, <i>n</i> (% of included)	Died, <i>n</i> (% of included) ^a	Follow-up time, years, mean (SD)	Crude mortality rate per 100 000 individuals per year
Benin (Sèmè-Kpodji)	363 (91)	358 (99)	5 (1)	6.45 (0.39)	214
Estonia (Tartu)	306 (100)	201 (66)	105 (34)	8.91 (2.81)	3851
Iceland (Reykjavik)	326 (92)	238 (73)	88 (27)	13.05 (3.28)	2068
India (Kashmir)	59 (17)	53 (90)	6 (10)	9.62 (1.45)	1057
India (Mysore)	346 (99)	339 (98)	7 (2)	7.49 (2.55)	270
India (Pune)	341 (99)	323 (95)	18 (5)	10.77 (1.48)	490
Jamaica	161 (47)	157 (98)	4 (2)	5.75 (0.52)	432
Kyrgyzstan (Chui)	581 (95)	561 (97)	20 (3)	6.26 (0.66)	550
Kyrgyzstan (Naryn)	529 (99)	509 (96)	20 (4)	6.14 (0.69)	616
Malawi (Chikwawa)	204 (94)	195 (96)	9 (4)	4.65 (0.79)	949
Morocco (Fes)	92 (22)	90 (98)	2 (2)	10.64 (1.19)	204
Nigeria (Ife)	525 (98)	500 (95)	25 (5)	8.23 (1.00)	579
Norway (Bergen)	314 (94)	248 (79)	66 (21)	13.68 (3.20)	1536
Pakistan (Karachi)	294 (85)	270 (92)	24 (8)	4.27 (0.76)	1912
Philippines (Nampicuan-Talugtug)	364 (99)	315 (88)	49 (13)	10.07 (1.87)	1337
Sudan (Khartoum)	35 (17)	35 (100)	0 (0)	7.87 (0.47)	n/a
Sweden (Uppsala)	245 (92)	219 (89)	26 (11)	12.42 (1.94)	854
Tunisia (Sousse)	270 (77)	251 (93)	19 (7)	10.37 (0.99)	670
Total	5355 (81)	4861 (91)	493 (9)	8.51 (3.26)	1082
Total^b	5228 (87)	4737 (91)	491 (9)	8.47 (3.28)	1109

^a Excluding deaths from accidents and violence.^b Excluding Morocco (Fes) and Sudan (Khartoum).

Table 2 Baseline characteristics of study participants included in the survival analysis (excluding those who could not be contacted and those who died of accidental deaths) stratified by sex and study site.

A. Men										
Study site	N	Age, mean (SD)	Weight, mean (SD)	Height, mean (SD)	Ever smoked (%)	Current smoking (%)	Pack years of smoking	FEV ₁ , mean (SD)	FVC, mean (SD)	FEV ₁ /FVC, mean (SD)
Benin (Sèmè-Kpodji)	279	52.9 (10.0)	71.7 (13.9)	170.7 (6.2)	14 (5.0)	12 (4.3)	0.5 (3.1)	2.60 (0.53)	3.30 (0.62)	0.787 (0.067)
Estonia (Tartu)	313	60.1 (11.7)	88.2 (16.6)	176.3 (7.1)	200 (63.9)	76 (24.3)	13.7 (17.2)	3.45 (0.82)	4.51 (0.90)	0.761 (0.082)
Iceland (Reykjavik)	364	56.0 (11.3)	91.7 (16.1)	179.4 (6.5)	257 (70.6)	75 (21.4)	14.8 (30.4)	3.56 (0.82)	4.67 (0.91)	0.758 (0.087)
India (Kashmir)	76	52.9 (11.1)	59.6 (9.3)	165.2 (6.3)	61 (80.3)	55 (72.3)	241.4 (295)	2.75 (0.83)	3.72 (0.70)	0.727 (0.121)
India (Mysore)	257	47.9 (8.2)	65.4 (9.5)	163.1 (5.7)	58 (22.6)	55 (21.4)	3.3 (8.7)	2.42 (0.69)	3.07 (0.75)	0.781 (0.085)
India (Pune)	496	53.2 (10.5)	59.8 (11.3)	163.8 (6.8)	102 (20.6)	78 (15.7)	1.1 (4.0)	2.46 (0.54)	3.11 (0.58)	0.789 (0.084)
Jamaica	143	57.5 (12.3)	69.9 (13.9)	171.2 (8.5)	91 (63.6)	47 (32.9)	26.1 (46.5)	2.77 (0.71)	3.58 (0.76)	0.770 (0.103)
Kyrgyzstan (Chui)	257	52.6 (9.2)	75.7 (14.6)	169.3 (6.9)	200 (77.8)	135 (52.5)	20.2 (22.8)	3.19 (0.74)	4.27 (0.77)	0.744 (0.097)
Kyrgyzstan (Naryn)	318	52.5 (10.1)	71.1 (12.4)	167.8 (6.3)	192 (60.4)	121 (38.1)	11.1 (15.3)	3.28 (0.65)	4.30 (0.73)	0.761 (0.084)
Malawi (Chikwawa)	206	55.0 (10.5)	57.2 (9.1)	166.2 (8.3)	98 (49.8)	64 (32.5)	4.1 (7.8)	2.65 (0.59)	3.55 (0.61)	0.746 (0.102)
Morocco (Fes)	112	54.8 (8.9)	74.2 (12.3)	168.8 (7.0)	70 (62.5)	24 (21.4)	16.2 (28.1)	3.15 (0.58)	3.99 (0.63)	0.787 (0.071)
Nigeria (Ife)	334	56.0 (12.3)	68.0 (13.3)	168.5 (6.7)	80 (24.0)	24 (7.2)	1.7 (7.2)	2.48 (0.62)	3.20 (0.66)	0.773 (0.093)
Norway (Bergen)	308	59.3 (12.6)	85.0 (14.6)	177.6 (7.2)	221 (71.8)	87 (28.3)	15.4 (17.2)	3.39 (0.84)	4.54 (0.94)	0.739 (0.095)
Pakistan (Karachi)	221	54.1 (9.3)	70.6 (16.0)	166.6 (8.1)	111 (50.5)	66 (30.0)	13.2 (29.7)	2.39 (0.65)	3.05 (0.72)	0.777 (0.104)
Philippines (Nampicuan-Talugtug)	354	53.7 (10.7)	57.9 (11.0)	164.3 (7.1)	272 (76.8)	182 (51.4)	21.4 (21.2)	2.46 (0.69)	3.22 (0.69)	0.755 (0.116)
Sudan (Khartoum)	42	52.9 (8.0)	75.3 (13.9)	171.4 (8.1)	26 (61.9)	15 (35.7)	11.3 (17.7)	2.67 (0.61)	3.40 (0.73)	0.783 (0.065)
Sweden (Uppsala)	263	58.5 (10.9)	86.4 (13.0)	178.0 (7.0)	181 (68.8)	35 (13.3)	12.4 (19.1)	3.53 (0.82)	4.67 (0.91)	0.754 (0.086)
Tunisia (Sousse)	229	53.2 (9.9)	78.4 (14.6)	170.1 (6.0)	180 (78.6)	120 (52.4)	28.8 (26.9)	3.10 (0.74)	3.98 (0.77)	0.774 (0.091)
Total	4572	54.7 (11.1)	72.8 (17.4)	170.0 (8.7)	2414 (52.9)	1274 (27.9)	15.5 (52.6)	2.91 (0.82)	3.80 (0.98)	0.765 (0.093)
B. Women										
Study site	N	Age, mean (SD)	Weight, mean (SD)	Height, mean (SD)	Ever smoked (%)	Current smoking (%)	Pack years of smoking	FEV ₁ , mean (SD)	FVC, mean (SD)	FEV ₁ /FVC, mean (SD)
Benin (Sèmè-Kpodji)	363	50.0 (9.2)	72.3 (16.1)	160.6 (6.2)	0 (0.0)	0 (0.0)	0.0 (0.0)	1.94 (0.41)	2.42 (0.46)	0.801 (0.069)
Estonia (Tartu)	306	60.8 (12.1)	75.0 (15.1)	162.0 (6.4)	96 (31.4)	39 (12.8)	3.5 (7.6)	2.50 (0.68)	3.17 (0.77)	0.784 (0.072)
Iceland (Reykjavik)	326	56.5 (11.7)	76.0 (15.6)	165.8 (6.3)	202 (62.0)	73 (22.4)	10.0 (13.5)	2.55 (0.62)	3.31 (0.67)	0.765 (0.087)
India (Kashmir)	59	53.2 (11.7)	54.3 (11.1)	153.3 (6.3)	22 (37.3)	17 (28.8)	94.1 (207)	1.92 (0.52)	2.53 (0.48)	0.755 (0.120)
India (Mysore)	346	45.9 (6.3)	59.7 (10.2)	155.2 (4.8)	5 (1.5)	4 (1.1)	0.1 (1.4)	1.79 (0.41)	2.22 (0.46)	0.806 (0.061)
India (Pune)	341	50.9 (8.5)	50.2 (10.0)	151.6 (6.1)	1 (0.3)	1 (0.3)	0.2 (2.8)	1.80 (0.37)	2.21 (0.40)	0.810 (0.072)

(continued)

Table 2 (continued)

B. Women

Study site	N	Age, mean (SD)	Weight, mean (SD)	Height, mean (SD)	Ever smoked (%)	Current smoking (%)	Pack years of smoking	FEV ₁ , mean (SD)	FVC, mean (SD)	FEV ₁ /FVC, mean (SD)
Jamaica	161	56.3 (11.5)	79.3 (18.6)	161.4 (6.5)	27 (16.8)	11 (6.8)	2.2 (9.3)	1.94 (0.48)	2.46 (0.52)	0.787 (0.094)
Kyrgyzstan (Chui)	581	52.5 (9.1)	72.9 (14.6)	157.3 (6.7)	44 (7.6)	27 (4.7)	0.9 (5.3)	2.36 (0.49)	3.00 (0.56)	0.788 (0.070)
Kyrgyzstan (Naryn)	529	53.0 (10.3)	68.0 (13.6)	155.4 (6.3)	13 (2.5)	2 (0.4)	0.1 (1.8)	2.36 (0.47)	2.98 (0.53)	0.791 (0.061)
Malawi (Chikwawa)	204	52.8 (10.4)	55.6 (11.9)	156.4 (7.2)	23 (11.6)	9 (4.5)	1.1 (4.9)	2.11 (0.42)	2.69 (0.48)	0.783 (0.072)
Morocco (Fes)	92	52.7 (9.3)	73.7 (12.5)	156.4 (6.4)	0 (0.0)	0 (0.0)	0.0 (0.0)	2.35 (0.50)	2.93 (0.59)	0.801 (0.063)
Nigeria (Ife)	525	54.8 (11.6)	66.6 (15.5)	159.0 (5.8)	20 (3.8)	1 (0.2)	0.1 (1.1)	1.87 (0.43)	2.34 (0.46)	0.795 (0.075)
Norway (Bergen)	314	60.4 (12.5)	70.8 (12.6)	164.4 (6.5)	183 (58.3)	87 (27.7)	10.2 (15.1)	2.48 (0.61)	3.27 (0.72)	0.755 (0.082)
Pakistan (Karachi)	294	49.2 (8.7)	65.7 (14.1)	154.3 (6.8)	26 (8.9)	16 (5.5)	2.8 (13.2)	1.76 (0.47)	2.15 (0.54)	0.822 (0.086)
Philippines (Nampicuan-Talugtug)	364	54.3 (10.4)	51.2 (10.9)	153.5 (6.0)	109 (30.0)	76 (20.9)	3.3 (7.4)	1.78 (0.47)	2.25 (0.51)	0.786 (0.094)
Sudan (Khartoum)	35	51.1 (10.9)	79.1 (17.8)	160.8 (7.4)	0 (0.0)	0 (0.0)	0.0 (0.0)	1.94 (0.47)	2.42 (0.55)	0.802 (0.062)
Sweden (Uppsala)	245	58.5 (10.7)	71.9 (14.4)	164.0 (6.2)	127 (51.8)	41 (16.7)	8.0 (12.1)	2.51 (0.60)	3.23 (0.67)	0.773 (0.075)
Tunisia (Sousse)	270	52.8 (8.8)	77.1 (13.4)	156.8 (6.7)	22 (8.2)	18 (6.7)	1.5 (6.9)	2.33 (0.58)	2.84 (0.63)	0.819 (0.054)
Total	5355	53.7 (10.9)	67.3 (16.3)	158.1 (7.4)	920 (17.2)	422 (7.9)	3.5 (25.0)	2.14 (0.58)	2.70 (0.69)	0.791 (0.077)

FVC, forced vital capacity; FEV₁, 1-s forced expiratory volume; SD, standard deviation.

the men and women were 55 (SD 11) and 54 (SD 11) years, respectively. The mean weight was 73 (SD 17) kg in men and 67 (SD 16) kg in women. Mean height was 170 (SD 9) cm in men and 158 (SD 7) cm in women. Just over half (53%) of men and 17% of women had ever smoked, and 28% of men and 8% of women were current smokers at the time of the baseline survey. The mean FVC was 3.80 (SD 0.98) L in men and 2.70 (SD 0.69) L in women, and the mean FEV₁ was 2.91 (SD 0.82) L in men and 2.14 (SD 0.58) L in women. The mean FEV₁/FVC was 0.765 (SD 0.093) in men and 0.791 (SD 0.077) in women.

The proportion of participants followed up in the sites at Fes in Morocco (26%), Kashmir in India (19%), and Khartoum in Sudan (15%) was low due to the COVID-19 pandemic. Data from the sites in Morocco and Sudan were excluded from the survival analysis due to the small number of study participants recorded as dying (two in each site). The total number of study participants included in the survival analysis was 9927, of whom 1147 (10.5%) were reported dead at the follow-up. The mean (SD) follow-up time was 8.67 (3.30) years.

Figure 2 is a forest plot that shows the association between mortality and FVC as hazard ratios for men and women for each study site grouped by geographical region. There is considerable variation overall, but differences between regions are not significant ($P=0.21$ for men and $P=0.50$ for women). The hazard ratio associated with a 1 l increase in FVC is 0.52 [95% confidence interval (CI): 0.38, 0.71] for men and 0.59 (95% CI: 0.44, 0.80) for women.




Figure 2 Forest plots of the association of forced vital capacity (FVC) with mortality by region and site (hazard ratios per 1 l increase in FVC adjusted for age, smoking status, height, and weight).

Figure 3 shows the association of mortality with the FEV₁/FVC ratio for men and women. There is little heterogeneity between regions among the men ($P=0.38$), but there is heterogeneity among the women at both the site level and across regions ($P=0.03$). The hazard ratio associated with a 10% increase in FEV₁/FVC is 0.81 (95% CI: 0.75, 0.88) for men and 0.89 (95% CI: 0.73, 1.10) for women.

Table 3 summarizes these associations per SD of lung function measurement and shows the independent effects of FVC and FEV₁/FVC ratio. After adjusting for age, smoking status, height, and weight, and mutually adjusting for FVC and FEV₁/FVC, the hazard ratios for men are 0.56 (95% CI: 0.42, 0.75) per SD of FVC and 0.86 (95% CI: 0.80, 0.92) per SD of FEV₁/FVC ratio. The hazard ratios per SD for women were 0.72 (95% CI: 0.59, 0.89) for the FVC and 0.93 (0.79, 1.10) for the FEV₁/FVC ratio. Figure 4 shows that in both sexes, mortality is lower where the FVC is higher.

Discussion

This study has confirmed the association between FVC and all-cause mortality and that this association appears stronger than that between longevity and the FEV₁/FVC ratio. The association of the FEV₁/FVC ratio with mortality after adjusting for smoking was only significant among men. This weak association confirms earlier findings from the USA [2, 3].




Figure 3 Forest plots of the association of forced expiratory volume in 1 second to forced vital capacity ratio (FEV_1/FVC) with mortality by region and site (hazard ratios per 10% increase in the ratio adjusted for age, smoking status, height and weight).

Table 3 Association of spirometric measurements with mortality.

	Unadjusted		Adjusted ^a		Mutually adjusted ^b	
	HR	95% CI	Adj. HR	95% CI	Adj. HR	95% CI
Men						
FVC	0.37	(0.31, 0.45)	0.52	(0.38, 0.71)	0.56	(0.42, 0.75)
FEV_1	0.42	(0.35, 0.49)	0.60	(0.47, 0.77)	–	–
FEV_1/FVC	0.68	(0.58, 0.70)	0.82	(0.77, 0.89)	0.86	(0.80, 0.92)
Women						
FVC	0.39	(0.32, 0.48)	0.70	(0.57, 0.85)	0.72	(0.59, 0.89)
FEV_1	0.41	(0.35, 0.50)	0.73	(0.64, 0.83)	–	–
FEV_1/FVC	0.70	(0.61, 0.80)	0.92	(0.78, 1.08)	0.93	(0.79, 1.10)

Coefficients are per standard deviation to allow better comparison between lung function measurements.

FVC, forced vital capacity; FEV_1 , 1-s forced expiratory volume; HR: hazard ratio; Adj: adjusted; CI: confidence interval.

^a Adjusted for age, smoking status, height and weight.

^b Mutually adjusted for FVC, FEV_1 , age, smoking status, height, and weight.

It also shows that the association between FVC and mortality is constant across broad geographic regions. This is in spite of the wide heterogeneity in the association of FVC with age and height [11] and wide variations in mortality [12]. This is compatible with the conclusion of the American Thoracic Society

statement, which noted that using ethnic adjustments to spirometric measurements is inappropriate when assessing prognosis [13]. It extends the evidence for this conclusion to include a wide variety of populations outside the USA. We did not look at ethnicity specifically, as most study sites were ethnically




Figure 4 Distribution of forced vital capacity (FVC) (centiles) and its relationship with mortality using Burden of Obstructive Lung Disease (BOLD) study global reference equations (unadjusted for region). Centiles taken from the global values in Burney et al. [7]

homogeneous, and ethnicity is hard to define. However, if ethnicity was important, we would have seen a regional difference in our results, and we did not.

We used random-effects meta-analysis to combine results. This gives broader confidence intervals than fixed-effects analysis, but is justified by the results that show substantial variation in results between sites.

The BOLD study has many strengths when answering the question of whether a single standard can be used to assess spirometric values. It uses a standardized protocol across all study sites. It covers a wide geographical area with a known variation in mean FVC and in the relation of the FVC to age and height [11]. The spirometry was quality controlled both by training all of the technicians involved in the study and by over-reading the spirometry centrally and asking for technicians whose quality started to fail to be retrained before continuing. This level of quality assurance has been shown to be essential in studies of lung function [14, 15]. The overall follow-up rate was 79.4%, and 11/18 (61%) sites had a >90% retention.

In low-income countries, mortality was estimated using information from relatives and neighbours. Other than excluding deaths from accidents and violence, we did not attempt to assess the cause of death. The fact of death, if reported, was regarded as reliable.

The COVID-19 pandemic made serious difficulties in some sites, and some of them did not complete the follow-up study. This may have weakened the power of the study, but we do not believe that it had any material influence that might have altered the conclusions from the analysis. Those lost to follow-up were slightly older and substantially more likely to be never smokers [13] but were otherwise similar at baseline to those who were followed up. We used inverse probability weighting to reduce any bias due to differential follow-up. Participants who were unable to provide adequate spirometry at baseline were

excluded from the follow-up. It has been shown that these people have a worse prognosis, but their exclusion is unavoidable and unlikely to have altered the conclusions from our analysis. Although there was reasonable representation of the four broad geographical regions identified in the BOLD baseline survey, there are large areas that are not represented in the follow-up, most prominently China and the affluent countries of South-East and East Asia.

Our analysis used the Cox proportional hazards method. This method allows a parametric analysis of multiple variables simultaneously but assumes that the hazards are proportional. We tested this assumption in all the sites using Schoenfeld residuals and only two sites, Reykjavik and Mysore, infringed this assumption in the model for FVC in men, and only two sites, Reykjavik and Ife, among women. When these sites were removed from the analysis, there was very little change in the results (Supplementary Table 2, in the supplementary material).

We have focused our analysis on two main spirometric measurements, the FVC, a measurement of lung size, and the FEV₁/FVC ratio, which is a measure of airflow adjusted for lung size. It has been common for the FEV₁ alone to be used as a marker of ventilatory inadequacy [16, 17], and it has been suggested that this is a more reliable marker of outcome [18, 19]. Fletcher et al. used the FEV₁ by itself because they suspected early on that their FVC measurements were unreliable. This is a common problem, as the FVC is a more difficult measurement. The FEV₁ is, besides this, highly correlated with the FVC, and it is not entirely irrational to use this as a proxy for the FVC or the TLC. The main problem with this practice is that it leads to the erroneous impression that it is airflow obstruction that is driving mortality. Here, we show that it is the FVC (lung size) and not the FEV₁/FVC (airflow adjusted for lung size) that is more strongly associated with mortality. This confirms the conclusions from earlier

analyses of the Cardiovascular Health Study [2] and the Atherosclerosis Risk in Communities Study [3].

Those who have a low FVC have a similar prevalence of dyspnoea as do those with a low FEV₁/FVC ratio [20], and cases with a low FVC, in the absence of spirometry, are likely to be misdiagnosed as having airflow obstruction, particularly in the countries of South, Southeast and East Asia, sub-Saharan Africa, and the Caribbean, where a low FVC is common [11]. The proximal and distal causes of death in these people are unclear, but it is unlikely to be respiratory failure. A low FVC is strongly associated with both diabetes and cardiovascular co-morbidities in all regions of the world [21] and is associated with central arterial stiffness [22, 23]. The name 'small lung syndrome' has been suggested to emphasize the close association between these three conditions [24]. The causes of the close association between these conditions are likely to arise in early life from shared risk factors [25], including low birth weight [26].

The analyses summarized in Fig. 4 show how FVC is related to mortality and suggest that a continuous risk could be provided based on outcomes. Moving from the use of arbitrary cut-offs, such as the lower limit of normal, to a continuous score of the FVC calibrated against outcomes, such as mortality, would provide a more rational basis for assessing prognosis than the use of 'normal values' on their own. The alternative is to define decision limits by estimating the values associated with particular outcomes or the relative benefits of intervention at different values [27]. This method has been used, for instance, to set limits for blood pressure in men and women [28]. The use of mortality as the outcome of choice has the advantage that it is clearly associated with the FVC, it has a clear definition, and is self-evidently of value to the individual. Establishing more precise risk scores will require larger cohorts of samples with good-quality spirometry and mortality data.

The use of regional adjustments for lung function is inappropriate when assessing survival but may be appropriate when making a diagnosis. The low FVC found very generally in Asia and Africa is part of what the CIBA symposium defined as 'non-specific lung disease' [29]. When considering the possibility of a specific restrictive lung disease such as sarcoidosis or silicosis, it would be appropriate to take account of the lower levels of vital capacity seen in the local population. The same dilemma does not occur when dealing with obstructive disease, as the FEV₁/FVC ratio does not vary from population to population in the same way [7, 30].

In conclusion, our findings emphasize the importance of a low FVC in determining high mortality rates in the Far East, Sub-Saharan Africa, and the Caribbean. They also support the recent American Thoracic Society Statement that adjustment of spirometric findings for ethnicity is inappropriate, at least when assessing prognosis [15]. It also extends the evidence for this advice beyond the USA to most of the world, including sub-Saharan Africa and the Far East. It further demonstrates how survival analysis can, in principle, provide interpretation of lung function that is linked to patient outcomes.

Ethics approval

All sites received approval from their local ethics committee, and the protocol was also approved by Imperial College London

Research Ethics Committee (ref. 17IC4272). All participants provided informed consent.

Acknowledgements

We thank all participants and staff for their time and effort put into this study.

Author contributions

A. Sonia Buist and Peter G.J. Burney were involved with the design of the original survey; Peter G.J. Burney and Andre F.S. Amaral designed the follow-up survey. The initial analysis was undertaken by Peter G.J. Burney and Emmanouil Bagkeris, and further analyses were undertaken by James Potts. Peter G.J. Burney wrote the first draft. All the other authors collected data, and all authors commented on an earlier draft of the paper and approved the final draft.

Supplementary material

Supplementary material is available at *IJE* online.

Conflicts of interest

R.N. reports grants from AstraZeneca and Sanofi outside of the submitted work. A.F.S.A. reports research grants from the COLT foundation outside of the submitted work. All other authors declare no competing interests.

Funding

The baseline study was supported by several funders, including the Wellcome Trust (085790/Z/08/Z). The follow-up study was funded by UK Medical Research Council (MR/R011192/1) and AstraZeneca AB (ESR-17-13417). For full details, see Amaral *et al.* [9]. The funders had no role in the analysis or interpretation of the findings.

Data availability

De-identified participant data and questionnaires may be shared, after publication, on a collaborative basis upon reasonable request made to Dr Amaral (a.amaral@imperial.ac.uk). Requesting researchers will be required to submit an analysis plan.

Use of artificial intelligence (AI) tools

AI was not used in the writing of this paper.

References

- Kannel WB, Lew EA, Hubert HB, Castelli WP. The value of measuring vital capacity for prognostic purposes. *Trans Assoc Life Insur Med Dir Am* 1980;**64**:66–83.
- Fried LP, Kronmal RA, Newman AB *et al.* Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. *JAMA* 1998;**279**:585–92.
- Burney PGJ, Hooper R. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. *Thorax* 2011;**66**:49–54.
- Burney PGJ, Hooper RJ. The use of ethnically specific norms for ventilatory function in African-American and white populations. *Int J Epidemiol* 2012;**41**:782–90.
- Gaffney AW, McCormick D, Woolhandler S *et al.* Prognostic implications of differences in forced vital capacity in Black and White US adults: findings from NHANES III with long-term mortality follow-up. *EClinicalMedicine* 2021;**39**:101073.
- McCormack M, Balasubramanian A, Matsui EC *et al.* Race, lung function, and long-term mortality in the National Health and Nutrition Examination Survey III. *Amer J Resp Crit Care Med* 2022;**205**:723–4.
- Burney PGJ, Potts J, Knox-Brown B *et al.* Geographical variation in lung function: results from the multicentric cross-sectional BOLD study. *Pulmonology* 2025;**31**:2430491.
- Buist AS, Vollmer WM, Sullivan SD *et al.* The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. *COPD* 2005;**2**:277–83.
- Amaral AFS, Potts J, Knox-Brown B *et al.*; BOLD Study Collaborative Network. Cohort profile: Burden of Obstructive Lung Disease (BOLD) study. *Int J Epidemiol* 2023;**52**:e364–e73.
- Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. *Epidemiology* 2004;**15**:615–25.
- Howe CJ, Cole SR, Lau B *et al.* Selection bias due to loss to follow up in cohort studies. *Epidemiology* 2016;**27**:91–7.
- Burney P, Jithoo A, Kato B *et al.*; Burden of Obstructive Lung Disease (BOLD) Study. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. *Thorax* 2014;**69**:465–73.
- Bhakta N, Bime C, Kaminsky DA *et al.* Race and ethnicity in pulmonary function test interpretation: an official American Thoracic Society statement. *Am J Respir Crit Care Med* 2023;**207**:978–95.
- Enright PL, Johnson LR, Connett JE *et al.* Spirometry in the lung health study. 1. Methods and quality control. *Am Rev Respir Dis* 1991;**143**:1215–23.
- Enright P, Vollmer WM, Lamprecht B *et al.* Quality of spirometry tests performed by 9893 adults in 14 countries: the BOLD Study. *Respir Med* 2011;**105**:1507–15.
- Fletcher C, Peto R, Tinker C, Speizer FE. *The Natural History of Chronic Bronchitis and Emphysema. An Eight-Year Study of Early Chronic Obstructive Lung Disease in Working Men in London.* Oxford: Oxford University Press, 1976.
- Vestbo J, Edwards LD, Scanlon PD *et al.*; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011;**365**:1184–92.
- Menezes AMB, Pérez-Padilla R, Wehrmeister FC *et al.*; PLATINO Team. FEV₁ is a better predictor of mortality than FVC: the PLATINO Cohort Study. *PLoS One* 2014;**9**:e109732.
- Bikov A, Lange P, Anderson JA *et al.* FEV₁ is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. *Int J Chron Obstruct Pulmon Dis* 2020;**15**:1135–42.
- Müller A, Wouters EF, Koul P *et al.* Association between lung function and dyspnoea and its variation in the multinational Burden of Obstructive Lung Disease (BOLD) study. *Pulmonology* 2025;**31**:2416815.
- Kulbacka-Ortiz K, Triest FJJ, Franssen FME *et al.* Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study. *Respir Res* 2022;**23**:34.
- Zureik M, Benetos A, Neukirch C *et al.* Reduced pulmonary function is associated with central arterial stiffness in men. *Am J Respir Crit Care Med* 2001;**164**:2181–5.
- Amaral AFS, Patel J, Gnatiuc L, Jones M, Burney PGJ. Association of pulse wave velocity with total lung capacity: a cross-sectional analysis of the BOLD London study. *Respir Med* 2015;**109**:1569–75.
- Burney P, Knox-Brown B, Amaral AFS. Small lung syndrome: the need to reclassify chronic lung disease. *Lancet Respir Med* 2023;**11**:405–6.
- Shaheen S. Early life origins of impaired adult lung function. In: PGJ Burney (ed.), *Small Lungs and Obstructed Airways, Reassessing Chronic Obstructive Airways Disease.* London, UK: Academic Press, 2025.
- Saad NJ, Patel J, Burney P, Minelli C. Birth weight and lung function in adulthood: a systematic review and meta-analysis. *Ann Am Thorac Soc* 2017;**14**:994–1004.
- Boyd JC. Defining laboratory reference values and decision limits: populations, intervals, and interpretations. *Asian J Androl* 2010;**12**:83–90.
- Gerdtz E, Sudano I, Brouwers S *et al.* Sex differences in arterial hypertension. *Eur Heart J* 2022;**43**:4777–88.
- Fletcher CM, Gilson J, Hugh-Jones P, Scadding JG. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions: a report of the conclusions of a CIBA guest symposium. *Thorax* 1959;**14**:286–99.
- Nafees AA, Muneer MZ, De Matteis S *et al.* Impact of using different predictive equations on the prevalence of chronic byssinosis in textile workers in Pakistan. *Occup Environ Med* 2022;**79**:242–4.